obesity patiennts
Conditions
Interventions
Semaglutide injection or tirzepatide injection
Sponsors
HEC Science Clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Obesity 2. Patients scheduled for semaglutide or tirzepatide administration 3. Indications for semaglutide: Obesity, provided that the patient has hypertension, dyslipidemia, and/or type 2 diabetes, impaired glucose imtoleranse, obstructive sleep apnea symdorome and dietary and exercise therapy alone are not enough to control body weight and metabolic disorders, limited to cases meeting the following criteria: > BMI is 27 kg/m2 or higher and has two or more obesity-related health issues > BMI is 35 kg/m2 or higher
Exclusion criteria
Exclusion criteria: 1.Individuals who do not consent to participate in the study 2.Those whom the principal investigator or co-investigator determines are not suitable to participate in this clinical research 3.Women who are pregnant or may be pregnant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Food Frequency Questionnaire (FFQ) and eating behavior assessments at 6 months before starting semaglutide or tirzepatide, at the time of initiation, and at 6, 12, and 18 months after starting | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in body mass index Change in body weight Change in waist circumference Change in blood pressure Change in pulse rate Change in HbA1c Change in blood glucose level Change in LDL-Cholesterol Change in HDL-Cholesterol Change in triglycerides Change in Aspartate Aminotransferase Change in Alanine Aminotransferase Change in Gamma-Glutamyl Transferase Change in body fat mass Change in muscle mass Change in skeletal muscle mass Change in basal metabolic rate Change in average energy expenditure Change in average step count | — |
Countries
Japan
Contacts
Public ContactHajime Maeda
HEC Science Clinic Department of Diabetes
Outcome results
None listed